Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- cardiac
- Genome
- Disease
- Diagnostic
- Delivery
- Antibody
- Assay
- Enzymes
- Therapeutic
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203266
License Grant
Licensor grants, during the Term, an exclusive license, under the Technology to Licensee Products in the Field.
License Property
This technology includes, without limitation, MYDICAR® (AAV1/SERCA2a).
Mydicar is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure. It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector.
Field of Use
The field is human therapeutics and prophylactics.
IPSCIO Record ID: 260408
License Grant
Licensor, an individual, hereby grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under Licensors interest in the Licensed Patents for any purpose in the Field, including, without limitation, to develop, make, have made, use, sell, offer for sale, have sold and import Products in the Field.
License Property
The patent relates to methods for transferring genes into the heart and blood vessels.
Field of Use
The Field shall mean the treatment or prevention of heart failure using products that act by the delivery of genes encoding proteins whose role is to regulate calcium uptake or release in the sarcoplasmic reticulum.
IPSCIO Record ID: 260407
License Grant
University grants to Licensee a license under Universitys interest in Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods in the Field, within the Territory and during the Term. The amendment adds the patent information.
The licenses granted in this paragraph is exclusive with respect to the Field only.
License Property
The patent is for the therapy treatment or prevention of cardiovascular disease.
Field of Use
The Field means gene therapy for the treatment or prevention of cardiovascular diseases by the delivery of a gene or a synthetic equivalent (DNA, deoxyribonucleic acid or polydeoxyribonucleotide sequence), in whole or in part or in combination, including those encoding one or more phospholamban genes and/or SERCA-2 (sacroplasmic reticulum calcium ATPase) genes, or their mutants, excepting the involvement of anti-sense RNA (ribonucleic acid or polyribonucleotide sequence) of the phospholamban gene.
IPSCIO Record ID: 260411
License Grant
Licensor grants a non-exclusive, worldwide license and sublicense, including the right to grant sublicenses through multiple tiers of sublicense, under the Patent Rights and Trade Secrets to make, have made, use, sell, have sold, offer for sale and import Licensee In Vitro Screening Reagents for use in the Field.
License Property
The patent is for Expression in Insect Cells of Genes with Overlapping Open Reading Frames, Methods and Compositions Therefor.
Licensee Product shall mean an adeno-associated virus with a SERCA2a transgene (AAV1/SERCA2a) enzyme replacement therapy, including, without limitation, Licensees proprietary MYDICAR product.
Field of Use
The purpose of this agreement is to develop a Licensee In Vitro Screening Reagent to be commercialized as part of an in vitro neutralizing antibody assay (NAb Assay) for use with Licensees Product.
The Field shall mean the performance of Tests to determine the suitability of patients for treatment with Licensee Product.
IPSCIO Record ID: 27836
License Grant
Mydicar is a gene therapy currently being developed by the Licensee to treat advanced heart failure utilizing targeted proprietary AAV-1 technology. Presently, without a transplant the vast majority of heart failure patients die within 5-7 years. May 30th, 2010, Licensee presented at the European Society of Cardiology in Berlin 6-month data from CUPID, its’ Phase II trial of Mydicar. Based on our due diligence at the ESCO conference and our confidence that the CUPID trial met and exceeded its’ endpoints, we believe it is very likely that the Licensee will initiate a Phase III trial for Mydicar within the next 6-9 months.
IPSCIO Record ID: 203262
License Grant
For a Research License, Licensor grants the Swiss Licensee a co-exclusive, worldwide right and license, without the right to grant sublicenses, under the Licensors Intellectual Property solely to enable Licensee to perform Licensee’s obligations under the Research Program during the Research Term.
For a Development and Commercialization License, Licensor grants an exclusive, worldwide right and license, with the right to grant sublicenses, under the Licensors Intellectual Property to Develop, Manufacture, have Manufactured, use, Commercialize and import Licensed Compounds and Licensed Products in the Field in the Territory, provided that Licensor shall retain rights sufficient to enable Licensor to perform its Development and Manufacturing obligations with respect to Licensed Compounds and Licensed Products hereunder, and to participate in the Co-promotion of Co-promoted Products.
License Property
The Licensed Compound relates to CRAC Channel Inhibitor, meaning any small molecule compound, and CRAC Channel, meaning the genes for the calcium release-activated calcium channel, also known by names including Orail, orai2, Orai3, CRACMl, CRACM2,.CRACM3 and proteins encoded by such genes.
Calcium release-activated channels (CRAC) are specialized plasma membrane Ca2+ ion channels. When calcium ions (Ca2+) are depleted from the endoplasmic reticulum (a major store of Ca2+) of mammalian cells, the CRAC channel is activated to slowly replenish the level of calcium in the endoplasmic reticulum.
Field of Use
Field means all human pharmaceutical and diagnostic uses, excluding medical device uses.
IPSCIO Record ID: 260409
License Grant
Licensor grants a non-exclusive, worldwide license, including the right to grant sublicenses through multiple tiers of sublicense, under the Patent Rights solely to develop, make, have made, use, offer for sale, sell, have sold, import, have imported, export and have exported Products in the Field of Use.
License Property
The patent relates to genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell.
Field of Use
The Field of Use shall mean the production and delivery of adeno-associate viral vector (AAV) Serotype 1 to deliver SERCA 2a for the treatment of heart failure and arrhythmias.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
